bluebird bio, Inc. (NASDAQ:BLUE) today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the U.S.
Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. livesAnticipate 85 to 105 patient starts
U.S. stocks traded mixed toward the end of trading, with the S&P 500 turning lower on Wednesday.
The Dow traded up 0.07% to 37,586.02 while the NASDAQ rose 0.17% to 15,029.36. The S&P 500, however, fell 0.04% to 4,766.46.
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 20 points on Wednesday.
The Dow traded up 0.06% to 37,581.68 while the NASDAQ rose 0.23% to 15,038.40. The S&P 500 also rose, gaining, 0.05% to 4,770.63.